2024 Revenues ($USD) : $7.81B

Grifols, the Barcelona-based player specializing in plasma, posted record numbers for the second year straight in 2024. Full-year revenue climbed 10.3% to land at €7.2 billion (that's about $7.8 billion USD). The momentum seemed to build towards year-end, with fourth-quarter revenue jumping 13.6%. CEO Nacho Abia highlighted this as setting the stage for sustainable, profitable growth.

The company laid out a pretty ambitious long-term plan, aiming to double revenue to €14 billion over the next ten years, targeting €10 billion in revenue and €2.9 billion in EBITDA by 2029. For the immediate future (2025), Grifols is projecting revenue around €7.6 billion (noting the impact of the U.S. Inflation Reduction Act), adjusted EBITDA between €1.88-€1.93 billion, and free cash flow pre-M&A in the €350-€400 million range.

Its growth playbook leans on pushing commercial growth in Biopharma, squeezing out better margins through plasma and manufacturing optimization, and delivering on the pipeline – with the upcoming fibrinogen therapy launch (slated for late 2025 in the EU, early 2026 in the U.S.) being a key piece.

From an analyst standpoint, Grifols' recent performance looks solid, suggesting its strategic investments are starting to pay off. While the long-term growth story fits with the increasing demand for plasma therapies, hitting those goals hinges heavily on execution, particularly around optimizing costs and margins. Eyes will be on the 2025 numbers versus guidance – especially that free cash flow figure – and how the critical fibrinogen launch shapes up. The long-term picture seems favorable given the market dynamics and high barriers to entry, although potential regulatory shifts affecting plasma always remain a background risk.